22nd Century Group, Inc. and GVB Biopharma have entered into an agreement with Cannabinoid API Solutions (CAS) and Transo-Pharm for global sales, marketing and distribution of GVB's Cannabinoid APIs. With more than 35 years of industry experience as a leading global supplier of pharmaceutical grade APIs, Transo-Pharm is a well-established supplier and distributor of pharmaceutical APIs to a broad portfolio of branded and generic finished drug product manufacturers, including more than 75 current active ongoing development programs. Transo-Pharm is partnered with an extensive range of reputable multinational pharmaceutical companies, all of which will have immediate access to GVB's cannabinoid APIs.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.829 USD | -4.16% | +23.93% | -72.17% |
05-30 | 22nd Century Group, Inc. Announces Resignation of John Miller as August 2, 2024 | CI |
05-15 | Transcript : 22nd Century Group, Inc., Q1 2024 Earnings Call, May 15, 2024 |
1st Jan change | Capi. | |
---|---|---|
-72.17% | 6.87M | |
+0.75% | 69.29B | |
+20.00% | 49.15B | |
+0.12% | 7.1B | |
-20.11% | 5.14B | |
-11.50% | 2.25B | |
-16.48% | 2.02B | |
-35.28% | 1.54B | |
-15.60% | 1.19B | |
-12.27% | 1.16B |
- Stock Market
- Equities
- XXII Stock
- News 22nd Century Group, Inc.
- 22Nd Century Group Announces New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs